Provid will employ its expertise in structure-based design, peptide mimetics technology, and medicinal chemistry to develop the lead compounds.
“We are pleased to be complementing the biology of Immune Control with Provid’s chemistry. This collaboration exemplifies the value of Provid’s drug discovery services in transforming targets into valuable drug candidates,” commented Dr Gary Olson, president & CEO of Provid.